{"id":5747,"date":"2025-07-31T23:06:46","date_gmt":"2025-07-31T23:06:46","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/07\/31\/readout-loud-podcast-fda-vinay-prasad-sarepta-duchenne-trump\/"},"modified":"2025-07-31T23:06:46","modified_gmt":"2025-07-31T23:06:46","slug":"readout-loud-podcast-fda-vinay-prasad-sarepta-duchenne-trump","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/07\/31\/readout-loud-podcast-fda-vinay-prasad-sarepta-duchenne-trump\/","title":{"rendered":"What Vinay Prasad\u2019s ouster means for biotech and the FDA"},"content":{"rendered":"<p>    What Vinay Prasad\u2019s ouster means for biotech and the FDA<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>This week\u2019s show is focused on a single topic \u2014 the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency\u2019s biologics division. This surprising development came after a series of controversial decisions he made on Sarepta\u2019s gene therapy for Duchenne muscular dystrophy and a barrage of political attacks from conservative voices.<\/p>\n<p>We bring on Brian Skorney, senior research analyst at Baird, to talk about the implications for the biotech industry. We then have on Robert Califf, former FDA commissioner, and Ned Sharpless, former acting FDA commissioner, to discuss the implications for the agency.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/07\/31\/readout-loud-podcast-fda-vinay-prasad-sarepta-duchenne-trump\/?utm_campaign=rss\">Read the rest\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Elaine Chen, Adam Feuerstein, and Matthew Herper<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/07\/31\/readout-loud-podcast-fda-vinay-prasad-sarepta-duchenne-trump\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>What Vinay Prasad\u2019s ouster means for biotech and the FDA This week\u2019s show is focused on a single topic \u2014 the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency\u2019s biologics division. This surprising development came after a series of controversial decisions he made on Sarepta\u2019s gene therapy for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2154,2146,2265],"tags":[2150],"class_list":["post-5747","post","type-post","status-publish","format-standard","hentry","category-biotechnology","category-fda","category-the-readout-loud","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5747"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=5747"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5747\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=5747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=5747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=5747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}